Fiche centre
Research Site
Nagoya — Japan
Essais liés3clinical trials
VilleNagoyalocalisation
PaysJapanlocalisation
SourcelocaleCSV/MySQL
Informations
centreSynchronisé depuis ClinicalTrials.gov — NCT04877691
Essais cliniques associés
3| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| ALXN1720 | Myasthénie | Phase 3 | NCT05556096 | Safety and Efficacy of ALXN1720 in Adults With Generalized Myasthenia Gravis | ACTIVE_NOT_RECRUITING |
| Medi-546 | Lupus | Phase 3 | NCT04877691 | Tulip SC — Subcutaneous Anifrolumab in Adult Patients With Systemic Lupus Erythematosus | ACTIVE_NOT_RECRUITING |
| Trastuzumab deruxtecan | Parkinson | Phase 3 | NCT06989112 | DE-01 — DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer | RECRUITING |